Fig. 3From: First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patientsMedian logarithmic reduction in serum HBcrAg at week 48 and week 96 of NA in HBeAg-negative patientsBack to article page